Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)

NCT07119970 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT07119970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07119970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)
Lead sponsor
University Hospital, Bordeaux
Phase
Not applicable
Overall status
Recruiting
Start date
December 9, 2025
Completion date
December 31, 2030
Enrollment
300 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative disorders, myeloproliferative neoplasm